ITRM Iterum Therapeutics plc

2.69
-0.02  -1%
Previous Close 2.71
Open 2.71
Price To Book -1.53
Market Cap 39,997,537
Shares 14,868,973
Volume 29,783
Short Ratio
Av. Daily Volume 68,166
Stock charts supplied by TradingView

NewsSee all news

  1. Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)

    Topline results from uUTI and cUTI clinical trials to be announced in Q2 2020 Iterum Therapeutics maintaining business operations amid COVID-19 public health crisis DUBLIN, Ireland and CHICAGO, March 31, 2020 (GLOBE

  2. Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

     --Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1----NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 (GLOBE NEWSWIRE) --

  3. Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    DUBLIN, Ireland and CHICAGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat

  4. Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors

    DUBLIN, Ireland and CHICAGO, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV

  5. Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection

    DUBLIN, Ireland and CHICAGO, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due early-2Q 2020.
Sulopenem
Uncomplicated urinary tract infections (uUTI)
Phase 3 data due early-2Q 2020.
Sulopenem
Complicated urinary tract infections (cUTI)
Phase 3 data missed primary endpoint - December 10, 2019.
Sulopenem
Complicated intra-abdominal infections (cIAI)
Enrolment of first patient announced March 31, 2020.
IFX-1
COVID-19 Coronavirus

Latest News

  1. Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)

    Topline results from uUTI and cUTI clinical trials to be announced in Q2 2020 Iterum Therapeutics maintaining business operations amid COVID-19 public health crisis DUBLIN, Ireland and CHICAGO, March 31, 2020 (GLOBE

  2. Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

     --Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1----NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 (GLOBE NEWSWIRE) --

  3. Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    DUBLIN, Ireland and CHICAGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat

  4. Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors

    DUBLIN, Ireland and CHICAGO, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV

  5. Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection

    DUBLIN, Ireland and CHICAGO, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat

  6. Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections

    DUBLIN, Ireland and CHICAGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company focused on developing an oral and IV penem antibiotic to treat infections

  7. Iterum Therapeutics Reports Third Quarter 2019 Financial Results and Highlights

    --Phase 3 topline data from the cIAI trial expected shortly-- --cUTI and uUTI Phase 3 trials remain on track to complete enrollment around year-end and report topline data in Q1 2020-- -- NDA Filings Expected in

  8. Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

    WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven

  9. Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

    DUBLIN, Ireland and CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat